|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
18
|
|
pubmed:dateCreated |
2010-11-29
|
|
pubmed:abstractText |
To determine activity and safety of capecitabine at a moderate dose of 2000 mg/m(2) as first-line therapy for metastatic breast cancer.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1879-0852
|
|
pubmed:author |
pubmed-author:BauerWW,
pubmed-author:CostaS DSD,
pubmed-author:DistelrathAA,
pubmed-author:GBG-39 Trialists,
pubmed-author:GerberBB,
pubmed-author:HagenVV,
pubmed-author:KaufmannMM,
pubmed-author:Kleine-TebbeAA,
pubmed-author:LoiblSS,
pubmed-author:MaassNN,
pubmed-author:MehtaKK,
pubmed-author:RallK LKL,
pubmed-author:RuckhaeberleEE,
pubmed-author:SütterlinM WMW,
pubmed-author:SchneeweissAA,
pubmed-author:SchraderII,
pubmed-author:WiestWW,
pubmed-author:von MinckwitzGG
|
|
pubmed:copyrightInfo |
Copyright © 2010 Elsevier Ltd. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
46
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3184-91
|
|
pubmed:meshHeading |
pubmed-meshheading:20797843-Adult,
pubmed-meshheading:20797843-Aged,
pubmed-meshheading:20797843-Aged, 80 and over,
pubmed-meshheading:20797843-Antimetabolites, Antineoplastic,
pubmed-meshheading:20797843-Breast Neoplasms,
pubmed-meshheading:20797843-Breast Neoplasms, Male,
pubmed-meshheading:20797843-Deoxycytidine,
pubmed-meshheading:20797843-Disease Progression,
pubmed-meshheading:20797843-Disease-Free Survival,
pubmed-meshheading:20797843-Female,
pubmed-meshheading:20797843-Fluorouracil,
pubmed-meshheading:20797843-Humans,
pubmed-meshheading:20797843-Male,
pubmed-meshheading:20797843-Middle Aged,
pubmed-meshheading:20797843-Neoplasm Metastasis,
pubmed-meshheading:20797843-Prospective Studies,
pubmed-meshheading:20797843-Quality of Life
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial.
|
|
pubmed:affiliation |
Universitäts-Frauenklinik, Frankfurt, Germany.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
